CHRS – coherus biosciences, inc. (US:NASDAQ)

News

Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com